Chief Risk Officer — Mature-Brands Division

The mandate

A multinational-owned pharmaceutical enterprise has reprioritised late-stage assets, redirecting capital and senior attention away from parts of its mature-brands division. The brands still carry quality, safety, supply and regulatory obligations across numerous markets. The current CRO is leaving. An urgent replacement must ensure reduced strategic priority never becomes reduced control or slower escalation.

Approximately 800 employees and material partners span commercial, medical, regulatory, safety, quality, supply, finance and shared services from Singapore across the wider region. The CRO owns risk appetite, independent assurance, compliance coordination, incident oversight and board-committee reporting, reporting to the Group Chief Executive and relevant committee with unrestricted escalation.

Risk appetite must distinguish commercial priority from patient obligation. A brand may receive little new investment yet still require reliable supply, pharmacovigilance, complaint investigation, regulatory maintenance and truthful communication. The CRO will set minimum control and capacity thresholds below which management cannot reduce without explicit board decision.

Reprioritisation creates resource-allocation risk. Specialists may be moved to pipeline assets, leaving mature products dependent on single individuals or vendors. The CRO will require capability and succession evidence in workforce plans. Budget approval alone does not prove that obligations remain executable.

Supply decisions need independent challenge. Smaller batches, longer campaigns and higher inventory may be economically unattractive but necessary for continuity. The CRO will examine demand, expiry, alternate supply, quality and regulatory lead time. A cost target cannot dictate a shortage risk appetite implicitly.

Safety and medical-information routes must remain visible. Volumes may decline, causing channels to be consolidated or outsourced. The risk function will sample whether cases, questions and complaints reach authorised teams within time, including local language and after-hours sources.

Quality issue closure deserves scrutiny when management attention shifts. Investigations and corrective actions may compete with launch priorities. The CRO will verify effectiveness and aggregate recurring signals across brands and markets. Ageing will be reported by potential consequence, not merely action count.

Regulatory maintenance needs a forward view. Variations, renewals, commitments, labelling and local representation can fail if country expertise leaves. The CRO will establish obligation inventories and escalation before deadlines. Markets considered for withdrawal still require compliant execution through the approved exit.

Commercial conduct can change as teams defend declining revenue. Incentives may encourage channel loading, unsupported claims or unsuitable discount arrangements. The CRO will build case-based monitoring, review distributors and ensure leadership understands that decline does not relax conduct standards.

Third parties will carry more work. Distributors, manufacturers, call centres and regulatory agents need risk tiering by product consequence. Contracts, audit, data, continuity and incident routes will be examined. Outsourcing execution does not outsource accountability.

Data and technology reduction creates archival and access risk. Retiring systems or licences may remove records needed for safety, quality, regulatory or legal purposes. The CRO will challenge decommission gates and require retrieval tests. Sensitive data should remain protected even where active use falls.

Independent assurance will use product journeys and samples. First-line leaders will attest controls, but risk will test selected cases and physical or digital continuity. The CRO will coordinate with internal audit, quality and safety to avoid duplicate work while preserving independent opinions.

Board reporting will show residual exposure by product and market, control confidence, capability dependency and decision. Mature brands should not disappear inside aggregated enterprise heat maps. Where the CRO disagrees with resource removal, the committee should see the basis and proposed alternative.

What you will own

• Mature-brand risk appetite and minimum control.
• Quality, safety, regulatory and supply assurance.
• Capability and resource-reprioritisation challenge.
• Commercial conduct and distributor risk.
• Third-party, data and system continuity.
• Incident and issue effectiveness verification.
• Coordinated assurance and board reporting.
• Risk talent and succession.

The first 12 months

Within 30 days, identify brands and markets with weakened capability, test critical case routes and escalate any uncontrolled obligation. Propose minimum resource and control appetite.

By month five, complete product-level assurance, critical vendor reviews and archive tests. Implement conduct monitoring and obligation dashboards.

At twelve months, achieve 95% timely verified closure of high-risk actions, 100% current ownership for regulated product obligations and tested continuity for every critical third party. No material safety, regulatory or supply failure should arise from reprioritisation, while control cost reductions remain within board-approved appetite.

What the committee will inspect

• Strategic priority separated from regulated duty.
• Workforce moves preserving critical capability.
• Supply reductions supported by continuity evidence.
• Safety and complaint routes tested at low volume.
• Systems retired only after retrieval proof.
• Mature-brand exposure visible to the board.

The person

You bring 22–28 years in pharmaceutical risk, compliance, quality or regulated portfolio leadership, including CRO or substantial second-line authority in Asian markets. Your record includes mature products, resource reprioritisation and direct board challenge.

Candidates must show a reduction they opposed because product obligations remained and an activity safely simplified after evidence. The permanent onsite role is based in Singapore with unrestricted committee access.

Compensation and terms

Base compensation is SGD 420,000–570,000 plus annual incentive and long-term participation linked to risk appetite, control, product continuity, assurance and leadership. This permanent Singapore appointment works onsite and reports to the Group Chief Executive and relevant board committee. Replacement is urgent during active reprioritisation.

Confidentiality

The enterprise, brands, products, markets, incidents, controls, vendors and portfolio decisions remain confidential. Further information follows conflicts and signed confidentiality. Applicants must not contact pharmaceutical organisations or regulators to identify the client.